← Back to front page
United States · Platforms & data · MarketBeat

Anika Therapeutics' (ANIK) "Buy" Rating Reiterated at B. Riley Financial

Published by MarketBeat · United States 29 min ago
Image from MarketBeat Media, LLC.
Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

B. Riley Financial reissued a "buy" rating and set a $17.00 price objective (down from $23.00) on shares of Anika Therapeutics in a research note on Monday.

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading